Trial | Included VHD | Baseline Clinical Characteristics | |||||||
---|---|---|---|---|---|---|---|---|---|
Group | Age | CHADS2 | HAS-BLED | HTN | CVA | DM | MI | ||
ARISTOTLE* | Bioprosthetic valve | / | 71 (64, 77) | 2.2 ± 1.1 | N/A | 4102 (85.3) | 905 (18.8) | 1086 (22.6) | 837 (17.4) |
(Avezum et al., 2015) | Mitral valve repair | ||||||||
Native valve disease | |||||||||
ENGAGE AF-TIMI 48* (De Caterina et al., 2017) | Bioprosthetic valve | HDER | 71.8 ± 9.4 | 2.92 ± 1.0 | 2.55 ± 0.98 | 2629 (93.1) | 668 (23.7) | 908 (32.2) | 1122 (39.8) |
Mitral valve repair | LDER | ||||||||
Native valve disease | |||||||||
RE-LY | Native valve disease | Intervention: D110 | 74 (68, 78) | 2 (1,3) | N/A | 988 (76.5) | 279 (21.6) | 298 (23.1) | 251 (19.4) |
(Ezekowitz et al., 2016) | Intervention: D150 | 74 (67, 79) | 2 (1,3) | 1051 (77.7) | 310 (22.9) | 320 (23.7) | 250 (18.5) | ||
Control | 74 (68, 79) | 2 (1,3) | N/A | 1012 (77.5) | 286 (21.9) | 316 (24.2) | 212 (16.2) | ||
ROCKET AF* | Mitral valve repair | AS | 78 (73, 82) | 3.6 ± 0.9 | 3 ± 0.9 | 197 (92) | 99 (46) | 92 (43) | 64 (30) |
(Breithardt et al., 2016) | Native valve disease | MR/AR | 74 (67, 79) | 3.5 ± 1.0 | 2.8 ± 1.0 | 1542 (89) | 829 (48) | 690 (40) | 404 (23) |
Seeger et al. | Post-TAVI | / | 81.3 ± 5.9 | 4.9 ± 1.2 (CHA2DS2VASc) | 3.1 ± 1.1 | N/A | 35 (12.9) | 32.4 (88) | 19.5 (53) |
−2017 | |||||||||
(Geis et al., 2018) | Post-TAVI | Intervention | 83.1 ± 5.3 | 4.6 ± 1.2 (CHA2DS2VASc) | 2.7 ± 0.8 | 147 (95) | 24 (16) | 47 (31) | 80 (52) |
Control | 83.0 ± 4.9 | 4.8 ± 1.3 (CHA2DS2VASc) | 2.9 ± 0.8 | 158 (92) | 25 (15) | 57 (33) | 88 (51) |